

Mitsuteru Natsuizaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3266550/publications.pdf>

Version: 2024-02-01

69
papers

2,691
citations

201385

27
h-index

189595

50
g-index

70
all docs

70
docs citations

70
times ranked

4372
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 232.	1.7	6
2	Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0261760.	1.1	17
3	Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. <i>Carcinogenesis</i> , 2021, 42, 58-69.	1.3	21
4	Tenofovir disoproxil fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2021, 56, 168-180.	2.3	29
5	Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass. <i>Journal of Viral Hepatitis</i> , 2021, 28, 755-763.	1.0	6
6	Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0247728.	1.1	3
7	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. <i>Scientific Reports</i> , 2021, 11, 9207.	1.6	8
8	FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2021, 22, 372-380.	1.5	3
9	Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. <i>Nutrients</i> , 2021, 13, 2415.	1.7	8
10	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989.	1.8	20
11	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. <i>Cancers</i> , 2021, 13, 3633.	1.7	10
12	Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. <i>Scientific Reports</i> , 2021, 11, 16616.	1.6	6
13	Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2076-2087.	0.8	4
14	Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. <i>JGH Open</i> , 2020, 4, 54-60.	0.7	36
15	Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19. <i>Hepatology Research</i> , 2020, 50, 1196-1200.	1.8	11
16	Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. <i>JCSM Rapid Communications</i> , 2020, 3, 103-114.	0.6	8
17	Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. <i>Hepatology Research</i> , 2020, 50, 966-977.	1.8	35
18	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1782-1788.	1.4	22

#	ARTICLE	IF	CITATIONS
19	Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. <i>Hepatology Research</i> , 2020, 50, 715-725.	1.8	28
20	High serum angiotensin II level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. <i>Hepatology Research</i> , 2020, 50, 671-681.	1.8	20
21	Baseline angiotensin II and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 880-888.	0.7	13
22	Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 78-86.	2.3	19
23	Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. <i>Hepatology Research</i> , 2019, 49, 1294-1304.	1.8	32
24	Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs. <i>Hepatology Research</i> , 2019, 49, 1275-1285.	1.8	8
25	The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. <i>Internal Medicine</i> , 2019, 58, 943-947.	0.3	5
26	Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. <i>Hepatology Research</i> , 2019, 49, 1207-1217.	1.8	19
27	Metformin Regulates the Expression of CD133 Through the AMPK-CEBP β Pathway in Hepatocellular Carcinoma Cell Lines. <i>Neoplasia</i> , 2019, 21, 545-556.	2.3	28
28	Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 641-649.	2.3	21
29	Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. <i>Internal Medicine</i> , 2019, 58, 797-802.	0.3	4
30	Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. <i>Hepatology Research</i> , 2018, 48, 529-538.	1.8	15
31	Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. <i>Hepatology Research</i> , 2018, 48, E146-E154.	1.8	1
32	Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. <i>PLoS ONE</i> , 2018, 13, e0209615.	1.1	29
33	L-carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 910-922.	2.0	67
34	Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. <i>Journal of Hepatology</i> , 2017, 67, 1106-1108.	1.8	21
35	Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. <i>Journal of Gastroenterology</i> , 2017, 52, 1122-1129.	2.3	32
36	Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. <i>Hepatology Research</i> , 2017, 47, 1127-1136.	1.8	31

#	ARTICLE	IF	CITATIONS
37	Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. <i>Carcinogenesis</i> , 2017, 38, 1073-1083.	1.3	64
38	Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. <i>Nature Communications</i> , 2017, 8, 1758.	5.8	155
39	Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2017, 89, 857-866.	2.5	20
40	Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 101.	3.5	27
41	Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. <i>Hepatology Research</i> , 2016, 46, 1294-1303.	1.8	27
42	Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2016, 51, 733-740.	2.3	103
43	ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 593-599.	1.0	17
44	Human Amnion-Derived Mesenchymal Stem Cell Transplantation Ameliorates Dextran Sulfate Sodium-Induced Severe Colitis in Rats. <i>Cell Transplantation</i> , 2015, 24, 2601-2614.	1.2	46
45	Intratatumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2015, 40, 1492-1499.	2.0	31
46	A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1453-1461.	1.5	22
47	EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition. <i>Cancer Biology and Therapy</i> , 2015, 16, 933-940.	1.5	46
48	CTNNB1 mutational analysis of solid-pseudopapillary neoplasms of the pancreas using endoscopic ultrasound-guided fine-needle aspiration and next-generation deep sequencing. <i>Journal of Gastroenterology</i> , 2015, 50, 203-210.	2.3	33
49	Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. <i>Hepatology Research</i> , 2015, 45, 837-845.	1.8	15
50	Inhibition of Notch signaling enhances transdifferentiation of the esophageal squamous epithelium towards a Barrett's-like metaplasia via KLF4. <i>Cell Cycle</i> , 2014, 13, 3857-3866.	1.3	42
51	Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor- κ B/mitogen-activated protein kinase. <i>Carcinogenesis</i> , 2014, 35, 272-281.	1.3	32
52	Hepatosplenic Gamma-delta T-cell Lymphoma Associated with Epstein-Barr Virus. <i>Internal Medicine</i> , 2014, 53, 2079-2082.	0.3	6
53	IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. <i>American Journal of Cancer Research</i> , 2014, 4, 29-41.	1.4	50
54	Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. <i>Nature Protocols</i> , 2012, 7, 235-246.	5.5	138

#	ARTICLE	IF	CITATIONS
55	Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF α -mediated mRNA transcription and continuous protein synthesis. <i>FASEB Journal</i> , 2012, 26, 2620-2630.	0.2	44
56	The nuclear protein Artemis promotes AMPK activation by stabilizing the LKB1-AMPK complex. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 790-795.	1.0	4
57	Notch receptor inhibition reveals the importance of cyclin D1 and Wnt signaling in invasive esophageal squamous cell carcinoma. <i>American Journal of Cancer Research</i> , 2012, 2, 459-75.	1.4	20
58	A NOTCH3-Mediated Squamous Cell Differentiation Program Limits Expansion of EMT-Competent Cells That Express the ZEB Transcription Factors. <i>Cancer Research</i> , 2011, 71, 6836-6847.	0.4	99
59	MMP7 and activation of IGF-1R: A new insight into anti-EGFR therapeutic resistance in metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2011, 11, 184-187.	1.5	4
60	Epidermal Growth Factor Receptor and Mutant p53 Expand an Esophageal Cellular Subpopulation Capable of Epithelial-to-Mesenchymal Transition through ZEB Transcription Factors. <i>Cancer Research</i> , 2010, 70, 4174-4184.	0.4	128
61	Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis. <i>Carcinogenesis</i> , 2010, 31, 427-434.	1.3	104
62	Insulin-like growth factor-binding protein-3 promotes transforming growth factor- β 1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. <i>Carcinogenesis</i> , 2010, 31, 1344-1353.	1.3	72
63	Sensitive Assay for Quantification of Hepatitis B Virus Mutants by Use of a Minor Groove Binder Probe and Peptide Nucleic Acids. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4487-4494.	1.8	9
64	NOTCH1 and NOTCH3 Coordinate Esophageal Squamous Differentiation Through a CSL-Dependent Transcriptional Network. <i>Gastroenterology</i> , 2010, 139, 2113-2123.	0.6	107
65	Can Stressed Blood Cells Tell Cancer Risk in Inflammatory Bowel Diseases?. <i>Gastroenterology</i> , 2009, 137, 2174-2175.	0.6	0
66	Diffuse Large B-cell Lymphoma with Massive Portal Vein Tumor Thrombosis in a Patient with Alcoholic Cirrhosis: A Case Report and Literature Review. <i>Internal Medicine</i> , 2009, 48, 805-808.	0.3	17
67	8-Hydroxy-2'-deoxyguanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1431-1436.	1.4	58
68	Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. <i>Experimental Cell Research</i> , 2007, 313, 3337-3348.	1.2	72
69	Clinical features of hepatocellular carcinoma with extrahepatic metastases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1781-1787.	1.4	432